Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66

Report documents

1. Addendum

   Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66

   published on

   26.01.2021

   Document type

   PDF document, 130 kB, DE, not accessible

   Download file : Addendum (PDF document, 130 kB, DE, not accessible)

Additional information

Project details

Project no.

G20-32

Commission

Commission awarded on 22.12.2020 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Muscles, bones and joints

Note

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.

Connected Projects

1. Dossier assessment

   Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A20-66

   Last updated

   26.01.2021

   Status: Commission completed